How should linaclotide (Linzess) be started, what are its contraindications, common adverse effects, and alternative treatment options?

Linaclotide (Linzess) for Chronic Constipation

Linaclotide is strongly recommended for adults with chronic idiopathic constipation (CIC) who have not responded to over-the-counter laxatives, started at 72 mcg or 145 mcg once daily on an empty stomach at least 30 minutes before the first meal of the day. 1

Dosing and Administration

Starting dose:

• CIC in adults: 72 mcg or 145 mcg once daily 1
• IBS-C in adults: 290 mcg once daily 1
• Pediatric functional constipation (ages 6-17): 72 mcg once daily 2

Critical administration instructions:

• Take on an empty stomach at least 30 minutes before the first meal 1
• Can be used as replacement or adjunct to OTC agents 1
• No time limit specified on drug label for duration of treatment 1

Mechanism and Efficacy

Linaclotide is a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates GI transit 1. The evidence supporting its use is robust:

For CIC: Increases complete spontaneous bowel movements (CSBMs) by 1.37 per week, spontaneous bowel movements (SBMs) by 1.97 per week, and improves stool consistency significantly compared to placebo 1. The responder rate is 3 times higher than placebo (RR 3.14), translating to 119 more responders per 1,000 patients treated 1.

For IBS-C: Meets FDA endpoints with 34% of patients achieving combined improvement in abdominal pain and bowel function versus 19% with placebo 3. Also improves bloating, discomfort, and abdominal pain—making it particularly useful when these symptoms coexist with constipation 1.

Absolute Contraindications

Do not prescribe linaclotide in:

• Children under 2 years of age (risk of serious dehydration) 2
• Known or suspected mechanical GI obstruction 1, 2

Common Adverse Effects

Diarrhea is the primary adverse effect and occurs in a dose-dependent manner:

• 16-22% of patients on 145 mcg experience diarrhea versus 5-7% on placebo 2
• Most cases start within the first 2 weeks of treatment 2
• Severe diarrhea occurs in only 2% of patients 2
• Only 3-5% discontinue due to diarrhea 1, 2

Other adverse effects (<2% incidence):

• Abdominal pain (7% vs 5% placebo) 2
• Flatulence (6% vs 5% placebo) 2
• Defecation urgency, fecal incontinence 2
• Rare postmarketing: anaphylaxis, angioedema, hematochezia 2

Important clinical note: The most common reasons for discontinuation over the first year are loss of efficacy and insurance coverage barriers—NOT adverse events 1. This suggests the medication is generally well-tolerated in real-world practice.

Managing Diarrhea

When diarrhea occurs:

• Consider dose reduction (from 145 mcg to 72 mcg for CIC) 2
• Temporary suspension may be needed 2
• In long-term studies, 27% required dose adjustment, but most continued treatment 2

Counsel patients upfront about diarrhea risk and provide a plan for managing it if it occurs 4.

Special Populations

Older adults (≥65 years): No dose adjustment needed; efficacy comparable to younger patients 1

Hepatic impairment: No dose adjustment needed (negligible systemic absorption) 1

Pediatric patients (6-17 years): 72 mcg daily is FDA-approved for functional constconstipation with demonstrated efficacy and safety 5

Alternative Treatment Options

Before prescribing linaclotide for CIC, ensure patients have tried:

• Osmotic laxatives (polyethylene glycol, lactulose)
• Stimulant laxatives (bisacodyl, senna)

Other prescription alternatives with similar guideline support:

• Plecanatide (3 mg daily): Another guanylate cyclase-C agonist with similar efficacy profile 1
• Lubiprostone (24 mcg twice daily): Chloride channel activator; main adverse effect is nausea (35%) rather than diarrhea 1

The 2023 AGA-ACG guidelines give strong recommendations for all three agents (linaclotide, plecanatide, lubiprostone) with moderate certainty of evidence 1.

Long-Term Use

Linaclotide can be used continuously without tachyphylaxis 4. Studies up to 18 months show maintained efficacy 2. The drug should be taken continuously rather than sporadically for optimal benefit 4.

Key Clinical Pearls

• No systemic absorption: Linaclotide acts locally in the GI tract, minimizing systemic side effects 1
• Quality of life improvement: Beyond bowel symptoms, linaclotide improves constipation-related quality of life scores 1
• Coexisting abdominal symptoms: Particularly useful when bloating, discomfort, or pain accompany constipation 1
• Insurance barriers: Be prepared to address prior authorization requirements, as coverage issues are a common reason for treatment discontinuation 1